Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Group of biomarkers for predicting progression of intravenous leiomyomatosis

A biomarker, leiomyoma technology, applied in measurement devices, instruments, scientific instruments, etc., can solve the problems of judging IVL, not paying attention to patient metabolite changes, etc., achieving high accuracy, good clinical value, and operability strong effect

Active Publication Date: 2021-08-31
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, most studies only explore the potential regulatory genes that affect the pathogenesis and prognosis of IVL, and do not pay attention to the changes of a series of metabolites in patients
Therefore, there are currently no specific biochemical indicators to judge the diagnosis and prognosis of IVL.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group of biomarkers for predicting progression of intravenous leiomyomatosis
  • Group of biomarkers for predicting progression of intravenous leiomyomatosis
  • Group of biomarkers for predicting progression of intravenous leiomyomatosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The term IVL used in the present invention is an English abbreviation for intravenous leiomyomato-sis.

[0036] 1. Sample collection

[0037] This study complied with the Declaration of Helsinki and the Guidelines of the Clinical Practice Harmonization Conference, and was approved by the Ethics Committee of Peking Union Medical College Hospital (Ethics: JS-2654). All participants in the study signed informed consent. The disease group in this study included IVL patients who underwent surgery at Peking Union Medical College Hospital from December 2011 to May 2020 and were followed up regularly. The research population was divided into two groups: 30 healthy controls were the Co group, half of them had no uterine fibroids (Co-no), and the rest had uterine fibroids (Co-um); according to the postoperative recurrence, the 30 IVL patients were further divided into two groups. Divided into no recurrence group (IVL-no) and recurrence group (IVL-re). There were 15 samples in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a group of biomarkers for predicting the progression of intravenous leiomyomatosis, the biomarkers are hypoxanthine, glycerophosphorylcholine, acetylcarnitine and hydrocortisone (cortisol), and the overall trend of the expression quantity of the hypoxanthine and the glycerophosphorylcholine of the biomarkers is reduced along with the progression of the disease. The overall trend of the expression quantity of acetylcarnitine and hydrocortisone (cortisol) is increased along with disease progression. The invention also discloses a screening method of the biomarker for predicting the progress of the intravenous leiomyomatosis. The biomarkers hypoxanthine, glycerophosphorylcholine, acetylcarnitine and hydrocortisone (cortisol) are used for predicting the progress of the intravenous leiomyomatosis, have high specificity, are beneficial to early discovery and early treatment of the intravenous leiomyomatosis, and have good clinical use and popularization values.

Description

technical field [0001] The invention relates to the field of biological detection, in particular to a group of biomarkers for predicting the progression of intravenous leiomyomatosis. Background technique [0002] Intravenous leiomyomatosis (IVL) is a rare estrogen-dependent neoplastic disease. Although histologically benign, IVL is characterized by infiltrative growth. Tumors originate in the uterine vein wall or pelvic veins, can extend into the uterine or pelvic venous channels, invade through the iliac or ovarian veins, and extend to the inferior vena cava. Once the tumor enters the right atrium or right ventricle and pulmonary artery through the tricuspid valve, it will cause severe circulatory disturbance, which can lead to syncope or sudden death. If part of the tumor breaks off from the heart, it can lead to a life-threatening pulmonary embolism or cerebral infarction. Due to the unclear clinical symptoms and imaging manifestations of IVL, the rate of preoperative...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/72G01N30/86
CPCG01N30/02G01N30/72G01N30/8631
Inventor 葛志通冯鹏辉李建初张紫娟郁琦
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com